Alto vs Moderna
Side-by-side comparison of AI visibility scores, market position, and capabilities
Digital pharmacy with same-day delivery and transparent price comparison; concierge mobile app experience competing with Amazon Pharmacy and Capsule for urban medication delivery.
About
Alto Pharmacy is a digital pharmacy providing prescription delivery service with a concierge pharmacy experience — offering same-day or next-day delivery of prescriptions to customers' homes, transparent pricing (showing the lowest cost option including GoodRx discounts, insurance, or cash pay), and dedicated pharmacist support through the Alto mobile app. Founded in 2015 by Mattieu Gamache-Asselin and Jamie Karraker in San Francisco, Alto has raised approximately $350 million and operates in major US markets including San Francisco, Los Angeles, New York, Houston, and Denver.\n\nAlto's model combines an app-based pharmacy experience with local courier delivery infrastructure — customers transfer their prescriptions to Alto, and a courier delivers medications within hours. The app shows real-time prescription status, communicates with pharmacists through chat, and automatically compares pricing across insurance, manufacturer coupons, and GoodRx discounts to ensure the customer pays the lowest price. Proactive refill management and automatic renewal outreach reduce the friction of managing chronic medications.\n\nIn 2025, Alto competes with Amazon Pharmacy (backed by Amazon's logistics and Prime), Capsule (acquired by NovaBay Pharmaceuticals), PillPack (Amazon), Walgreens and CVS app-based delivery for on-demand pharmacy delivery. The retail pharmacy market is consolidating — independent pharmacies face PBM reimbursement pressure and CVS/Walgreens have been closing unprofitable locations. Alto's model of app + courier delivery + price transparency resonates with urban tech consumers. The 2025 strategy focuses on expanding specialty pharmacy capabilities (high-cost biologics and specialty medications that require complex handling), growing in new geographic markets, and deepening integrations with healthcare providers for seamless prescribing-to-delivery workflows.
mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.
About
Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.